Literature DB >> 28952030

Idiopathic hyperCKemia and malignant hyperthermia susceptibility.

Joilson M Santos1, Pamela V Andrade1, Leonardo Galleni2, Mariz Vainzof2, Claudia F R Sobreira3, Beny Schmidt4, Acary S B Oliveira4, José L G Amaral1, Helga C A Silva5.   

Abstract

PURPOSE: HyperCKemia is a persistent rise in serum creatine kinase (CK) levels of at least 1.5 times the normal value, as evidenced by a minimum of two measurements at 30-day intervals. One of the neuromuscular diseases associated with hyperCKemia is malignant hyperthermia (MH). This study investigated the susceptibility to MH in patients with hyperCKemia via in vitro contracture testing (IVCT) and a search of mutations in the RYR1 gene.
METHODS: Patients in an MH centre were followed from 1997-2012, and their epidemiologic, clinical, and laboratory data were analyzed, including IVCT, muscle histochemical analysis, and next-generation sequencing molecular analysis.
RESULTS: There were nine patients (eight male) in our study with a mean (SD) age of 33 (12) yr. Four patients were Caucasian and five were African Brazilian. Most complained about myalgia or cramps, but all had a normal neurological examination. They persistently presented with hyperCKemia from three months to ten years, with a mean (SD) CK value of 788 (507) IU·L-1 ranging from 210-1,667 IU·L-1. These values corresponded to a 1.5- to nine-fold increase in the normal value (mean increase, 3.7-fold). Six patients were MH susceptible (MHS) after a positive IVCT. Histopathological muscular analysis disclosed unspecified changes in four of the MHS patients. Mitochondrial proliferation was observed in the other two MHS patients and in three MH negative patients. No pathogenic mutations were identified in the RYR1 gene in the five patients evaluated.
CONCLUSION: When investigating patients with idiopathic hyperCKemia, susceptibility to MH should be taken into account, and guidance should be offered to prevent anesthetic complications in the family.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28952030     DOI: 10.1007/s12630-017-0978-x

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  5 in total

1.  Impact of a digital manual for guidance on malignant hyperthermia: patient education.

Authors:  Gislene Rodrigues; Pamela Vieira de Andrade; Joilson Moura Dos Santos; José Luiz Gomes do Amaral; Helga Cristina Almeida da Silva
Journal:  Orphanet J Rare Dis       Date:  2022-07-15       Impact factor: 4.303

2.  Association between known or strongly suspected malignant hyperthermia susceptibility and postoperative outcomes: an observational population-based study.

Authors:  Philip M Jones; Britney N Allen; Richard A Cherry; Luc Dubois; Kelly N Vogt; Salimah Z Shariff; Krista M Bray Jenkyn; Sheila Riazi; Duminda N Wijeysundera
Journal:  Can J Anaesth       Date:  2018-11-12       Impact factor: 5.063

3.  PharmGKB summary: very important pharmacogene information for CACNA1S.

Authors:  Katrin Sangkuhl; Robert T Dirksen; Maria L Alvarellos; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2020-02       Impact factor: 2.000

4.  Novel Variants in Individuals with RYR1-Related Congenital Myopathies: Genetic, Laboratory, and Clinical Findings.

Authors:  Joshua J Todd; Muslima S Razaqyar; Jessica W Witherspoon; Tokunbor A Lawal; Ami Mankodi; Irene C Chrismer; Carolyn Allen; Mary D Meyer; Anna Kuo; Monique S Shelton; Kim Amburgey; Dmitriy Niyazov; Pierre Fequiere; Carsten G Bönnemann; James J Dowling; Katherine G Meilleur
Journal:  Front Neurol       Date:  2018-03-05       Impact factor: 4.003

5.  [Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil].

Authors:  Helga Cristina Almeida da Silva; Gisele Ferreira; Gislene Rodrigues; Joilson Moura Dos Santos; Pamela Vieira Andrade; Alexandre Hortense; Marcelo Vaz Perez; José Luiz Gomes do Amaral
Journal:  Braz J Anesthesiol       Date:  2018-10-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.